👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Adtalem stock retains Outperform at BMO as FY2025 guidance exceeds consensus

Published 30/10/2024, 18:08
Adtalem stock retains Outperform at BMO as FY2025 guidance exceeds consensus
ATGE
-

On Wednesday, BMO Capital Markets adjusted its outlook on Adtalem Global Education (NYSE:ATGE), increasing the stock's price target to $90 from $84, while maintaining an Outperform rating. The revision came after Adtalem reported financial results that surpassed expectations on both revenue and earnings fronts.

Adtalem's recent performance was highlighted by accelerated enrollment growth across all three of its educational segments. Notably, the growth at Chamberlain and Walden exceeded the analyst's forecasts. The company also experienced a 130 basis point year-over-year expansion in adjusted EBITDA margins. Although some expenses are anticipated to shift into the second fiscal quarter of 2025, Walden in particular saw robust margin expansion.

Furthermore, Adtalem has updated its fiscal year 2025 guidance, now anticipating approximately a 2% increase in both top and bottom-line projections. The company is aiming for an 8% increase in revenue and a 17% increase in earnings for the year, which stands well above the consensus estimates.

The analyst's optimism is reflected in the revised estimates and the new price target, signaling confidence in Adtalem's growth trajectory and financial performance. The firm's analysis suggests that Adtalem is on track to outperform market expectations for the current fiscal year.

In other recent news, Adtalem Global Education has been making significant strides in its financial performance and strategic advancements. The company reported a robust year-over-year revenue increase of 9.2%, amounting to $1.58 billion, and a 10% rise in total enrollment.

The financial services firm, Baird, increased its stock price target for Adtalem shares to $93.00 from $87.00, maintaining an Outperform rating. BMO Capital Markets also maintained its Outperform rating for Adtalem, expressing increased confidence in the company's positioning within the healthcare education sector.

In addition, Adtalem successfully renegotiated the terms of its existing credit agreement with Morgan Stanley Senior Funding, Inc., leading to reduced interest rates for its term loans. Looking ahead, Adtalem anticipates another record year in 2025, projecting revenues between $1.66 billion and $1.7 billion and adjusted earnings per share of $5.60 to $5.85. These recent developments reflect Adtalem's positive growth strategy and potential for increased market share.

The raised guidance and better-than-expected enrollment figures have provided a positive signal for Adtalem's stock.

InvestingPro Insights

Adtalem Global Education's strong financial performance, as highlighted in the article, is further supported by recent data from InvestingPro. The company's revenue growth of 9.22% over the last twelve months and a notable 12.41% quarterly growth align with the reported accelerated enrollment growth across all segments. This robust growth is complemented by a healthy gross profit margin of 55.92%, indicating efficient cost management.

InvestingPro Tips suggest that Adtalem is trading at a low P/E ratio relative to its near-term earnings growth, with a PEG ratio of 0.31. This metric supports BMO Capital Markets' optimistic outlook and increased price target. Additionally, the company's profitability over the last twelve months and analysts' predictions of continued profitability this year reinforce the positive financial trajectory mentioned in the article.

It's worth noting that Adtalem has seen a significant price uptick of 51.13% over the last six months, reflecting market confidence in its performance and strategy. For investors seeking more comprehensive analysis, InvestingPro offers 8 additional tips for Adtalem Global Education, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.